In recent years, Glucagon-like peptide-1 receptor (GLP-1R) and its agonists have attracted much attention in the field of diabetes treatment
SIRs should be designed around a well-understood risk profile, not introduced as a default response to market pressure
This section investigates the particular benefits noted in clinical trials, emphasizing glycemic control and enhancements in lipid profiles
Research consistently shows that people on GLP-1 medications who don't prioritize protein lose significant amounts of muscle along with fat studies suggest up to 40% of weight lost can be lean muscle mass
Sustained intakes below ~1,200 kcal/day in women and ~1,5001,800 kcal/day in men jeopardize not only muscle mass, but also endocrine, neurologic, and micronutrient homeostasis
An easy rule of thumb is to aim for about one gram of protein per pound of ideal body weight